Samsung Bioepis reimagines and redefines the way medicines are made.
Samsung Bioepis is a biopharmaceutical company dedicated to unlocking the
potential of biosimilar medicines and transforming the way
biologic
therapies are brought to patients. Our mission is reflected in our name,
bio-epis; literally meaning life (“bio”) and science (“episteme”) in
Greek.
We want to enhance the lives of patients through our pioneering
and innovative use of science and technology.
Since our establishment in 2012, we have developed one of the most expansive and rapidly growing biosimilars portfolios in the industry. This enabled us to get 11 biosimilars approved and launched successfully in more than 40 countries, helping to improve the lives of patients through increased accessibility to medicines. We continue to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology.
We deliver high-quality biosimilars to patients across more than 40 countries through global commercial partnerships and direct commercialization network.
As long as patients face barriers to accessing the medicines they need, we will continue to strive for constant innovation. We are expanding into new areas of unmet need, we are also harnessing our smart development process for biosimilars to develop the next generation of novel biologics including ADC (Antibody Drug Conjugates). Our work has only just begun.
Since our launch in 2012, we have developed the industry’s most rapidly advancing biosimilar medicines portfolio and have become a leader in biosimilars.
i) We are in partnership with Organon, which spinoff from Merck in June 2021.
At Samsung Bioepis we believe our fresh approach to harnessing
science and technology is the key unlocking the health care of the future.
We will put our passion for health to work and strive for constant innovation.